Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia and includes discussion of future therapies that are currently in late stages of clinical evaluation.
Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia.
Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP) and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia.
外文書商品之書封，為出版社提供之樣本。實際出貨商品，以出版社所提供之現有版本為主。部份書籍，因出版社供應狀況特殊，匯率將依實際狀況做調整。
無庫存之商品，在您完成訂單程序之後，將以空運的方式為你下單調貨。為了縮短等待的時間，建議您將外文書與其他商品分開下單，以獲得最快的取貨速度，平均調貨時間為1~2個月。
為了保護您的權益，「三民網路書店」提供會員七日商品鑑賞期(收到商品為起始日)。
若要辦理退貨，請在商品鑑賞期內寄回，且商品必須是全新狀態與完整包裝(商品、附件、發票、隨貨贈品等)否則恕不接受退貨。
